Eurofins Selcia Limited is a UK-based limited company established in 2001, operating from its address in I54 Business Park, Wolverhampton, WV9 5GB. As a specialist in biotechnology research and development, Selcia focuses on providing comprehensive drug discovery services and custom-synthesized 14C radiolabeled compounds. The company’s core business centers around supporting pharmaceutical, biotechnology, and academic clients with crucial stages of drug development. Selcia’s expertise encompasses the entire lifecycle of a project, from initial compound design and synthesis to preclinical testing and analytical support. Selcia’s primary service offering involves the creation of high-quality, radiolabeled compounds, specifically designed for use in preclinical studies and analytical investigations. They cater to a diverse clientele, including clients requiring novel compounds for drug discovery, preclinical research, and analytical method development. The company operates under SIC codes related to biotechnology research and experimental development, with a focus on the wider industry of pharmaceuticals and related fields. Selcia is currently a Skilled Worker visa holder, and employees are rated as Workers (A rating). The company maintains an international presence, actively engaging with clients globally.

Eurofins Selcia Limited is a UK-based limited company established in 2001, operating from its address in I54 Business Park, Wolverhampton, WV9 5GB. As a specialist in biotechnology research and development, Selcia focuses on providing comprehensive drug discovery services and custom-synthesized 14C radiolabeled compounds. The company’s core business centers around supporting pharmaceutical, biotechnology, and academic clients with crucial stages of drug development. Selcia’s expertise encompasses the entire lifecycle of a project, from initial compound design and synthesis to preclinical testing and analytical support. Selcia’s primary service offering involves the creation of high-quality, radiolabeled compounds, specifically designed for use in preclinical studies and analytical investigations. They cater to a diverse clientele, including clients requiring novel compounds for drug discovery, preclinical research, and analytical method development. The company operates under SIC codes related to biotechnology research and experimental development, with a focus on the wider industry of pharmaceuticals and related fields. Selcia is currently a Skilled Worker visa holder, and employees are rated as Workers (A rating). The company maintains an international presence, actively engaging with clients globally.